Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 78, 2007, Pages 1612-1616

  Takahashi, Tsubasa ^a   Yoshida, Hiroshi ^a   Mamada, Yasuhiro ^a   Taniai, Nobuhiko ^a   Mizuguchi, Yoshiaki ^a   Shimizu, Tetsuya ^a   Kakinuma, Daisuke ^a   Ishikawa, Yoshinori ^a   Akimaru, Koho ^a   Sugisaki, Yuichi ^a   Tajiri, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Hepatocellular carcinoma

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; PHOSPHORYLASE; RNA DIRECTED DNA POLYMERASE; THYMIDYLATE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LIVER CELL CARCINOMA; MALE; MICRODISSECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DNA, COMPLEMENTARY; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICRODISSECTION; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 35948943907     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baba H, Teramoto K, Kawamura T, et al: Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and diseased livers. Cancer Chemother Parmacol 2003; 52:469-476.
2. Jiang W, Lu Z, He Y, et al: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3:395-399.
3. Hotta T, Kobayashi Y, Taniguchi K, et al: Thymidine phosphorylase and Dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer. Oncol Rep 2004; 12:347-351.
4. Kogure T, Ueno Y, Iwasaki T, et al: The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53:296-304.
5. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
6. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The rule of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13:1663-1670.
7. Johnston PG, Lenz H-J, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412.
8. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376.
9. Ichikawa W, Uetake H, Shirota Y, et al: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89:1486-1492.
10. Shirota Y, Stoelmacher J, Brabender J, et al: ERCC1 and thymidyrate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304.
11. Fink L, Seege W, Ermert L, et al: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998; 4:1329-1333.
12. Liver Cancer Study Group of Japan: The general rules for the clinical and pathological study of primary liver cancer (4th Edition). Kanehara, Tokyo, Japan 2000.
13. Lord RV, Salonga D, Danenberg KD, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, carinoma sequence. J Gastrointes Surg 2000; 4:135-142.
14. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 1996; 6:986-994.
15. Gibson UE, Geid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 1996; 6:995-1011.
16. Heidelberger C, Chaudhuri NK, Dannenberg P, et al: Fluorinated pyrimidine. A new class of tumor inhibitory compounds. Nature 1957; 179:663-666.
17. Fujisawa H, Terashima M, Irinoda T, et al: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 2002; 93:1342-1350.
18. Mori K, Hasegawa M, Nishida M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17:33-38.
19. Ishikawa Y, Kubota T, Otani Y, et al: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91:105-112.
20. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 1991; 68:499-501.
21. Johnson MR, Hageboutros A, Wang K, et al: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006-2011
22. Diasio RB, Johnson MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5:2672-2673.
23. McLeod HL, Sludden J, Murray GI, et al: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998; 77:461-465.
24. Edler D, Glimelius B, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predoctove marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20:1721-1728.
25. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12:2640-2647.
26. Takenoue T, Nagawa H, Matsuda K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7:193-198.
27. Kornmann M, Schwabe W, Sander S, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9:4116-4124
28. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 68:1903-1909.